Cambridge Epigenetix Stock

cambridge-epigenetix.comHealthcare / BioTech & PharmaFounded: 2012Funding to Date: $57.08MM

Cambridge Epigenetix (CEGX) is a life sciences tools and analytics company that has created a technology platform delivering step changes in both the type of information that can be generated from DNA and the cost at which it is gathered.

Register To Buy and Sell Shares

For more details on financing and valuation for Cambridge Epigenetix, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Cambridge Epigenetix’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Cambridge Epigenetix.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Joanne Mason Ph.D
Vice President, Biomarker Discovery
Vitali Proutski Ph.D
Vice President, Informatics
Bobby Yerramilli-Rao Ph.D
Co-Founder & Chairman
Shankar Balasubramanian
Co-Founder & Chairman of Scientific Advisory Board
Hayden Jeffreys
Chief Operating Officer
Deborah Tonge
Director of Finance
Jason Mellad Ph.D
Chief Executive Officer & Board Member

Board Members

Jason Mellad Ph.D
Shankar Balasubramanian
Tom Hulme
GV
Bobby Yerramilli-Rao Ph.D
Somasundaram Subramaniam
New Science Ventures
Alice Newcombe-Ellis
Ahren Innovation Capital
Martin Murphy Ph.D
Syncona
Roelof Botha
Sequoia Capital
Timothy Rink MD

Frequently Asked Questions About Cambridge Epigenetix’s Stock

plusminus
Can you buy Cambridge Epigenetix’s stock?
Cambridge Epigenetix is not publicly traded on NYSE or NASDAQ in the U.S. To buy Cambridge Epigenetix’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Cambridge Epigenetix’s stock?
Yes, you can sell stock of a private company like Cambridge Epigenetix. Forge can help you sell your Cambridge Epigenetix stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Cambridge Epigenetix’s stock price?
Cambridge Epigenetix is a privately held company and therefore does not have a public stock price. However, you may access Cambridge Epigenetix’s private market stock price with Forge Data.
plusminus
What is Cambridge Epigenetix’s stock ticker symbol?
Cambridge Epigenetix does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Google’s GV leads $21M Series B in bioscience firm Cambridge Epigenetix – TechCrunch
VC firm GV (née Google Ventures) has made another investment in Europe -- its seventh -- leading a $21 million Series B round for epigenetic sequencing tech company and Cambridge University spin-out, Cambridge Epigenetix.
Updated on: May 18, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.